WASHINGTON (dpa-AFX) - XDx, Inc. said it has entered into a collaboration and license agreement with Laboratory Corp. of America Holdings (LH), or LabCorp, whereby each party will collaborate in marker discovery, and LabCorp will develop and commercialize a diagnostic test to predict flares of systemic lupus erythematosus, or SLE.
According to Xdx, the agreement combines its autoimmune diagnostics research and discovery experience and SLE blood sample database with LabCorp's diagnostic development and commercialization resources. Financial terms of the agreement were not disclosed.
Pierre Cassigneul, XDx's president and chief executive officer, stated, 'Building upon our success in the immune-mediated diagnostic market with our first approved product, AlloMap Molecular Expression Testing, XDx is dedicated to expanding its pipeline of high value diagnostic tests to other diseases that involve the activity of the immune system. In lupus, we have developed an extensive, proprietary database of lupus blood samples that we will use in collaboration with LabCorp to initiate its development of a biomarker for the flare test. We look forward to a fruitful relationship with this world-class partner.'
Copyright RTT News/dpa-AFX
© 2012 AFX News
